drugset / Trial / NCT02259959

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

NCT02259959

Phase 1 Completed 36 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 1744 CL and Tiotropium Bromide when given as fixed dose combination

Timeline

Start
2007-04
Primary completion
2007-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Olodaterol Small molecule 2 ug Inhaled
Subject Olodaterol Small molecule 10 ug Inhaled
Subject Olodaterol Small molecule 40 ug Inhaled
Subject Tiotropium Other / unclassified 5 ug Inhaled
Subject Tiotropium Other / unclassified 10 ug Inhaled

Indications

No indication recorded.